Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Blood (2025) 146 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2025-1654

Published: 2025

Journal Articles

TP53 Deficiency in AML Confers Resistance to CAR T-Cells That Can be Overcome By Targeting the Cholesterol or Wnt Pathways

Jan Mueller, Roman Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Renier Myburgh, Laura Volta, Alexandre Theocharides, Kari Kurppa, Benjamin L. Ebert, Timm Schroeder, Markus G. Manz, Steffen Boettcher

Blood (2023) 142 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2023-185567

Published: 2023

Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134210

Published: 2020

Journal Articles

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Lijuan Han, MD, Marcelo A. Szymanski Toledo, PhD, Alexandre Theocharides, MD, Angela Maurer, M.Sc, Tim H. Brümmendorf, MD, Martin Zenke, PhD, Nicolas Chatain, PhD, Steffen Koschmieder, MD

Blood (2018) 132 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2018-99-113372

Published: 2018

Journal Articles

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Rouven Müller, MD, Alexandre Theocharides, MD, Renate Looser, Radek C. Skoda, M.D., Richard A. Flavell, PhD, Markus G. Manz, MD

Blood (2013) 122 (21): 2844.

https://doi.org/10.1182/blood.V122.21.2844.2844

Published: 2013

Journal Articles

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2 -V617F mutations

Sai Li, Robert Kralovics, Gennaro De Libero, Alexandre Theocharides, Heinz Gisslinger, Radek C. Skoda

Blood (2008) 111 (7): 3863–3866.

https://doi.org/10.1182/blood-2007-09-111971

Published: 2008

Includes: Supplemental data

Journal Articles

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Maurizio Ferrari, Heinz Gisslinger, Robert Kralovics, Laura Cremonesi, Radek Skoda, Mario Cazzola

Blood (2008) 111 (3): 1686–1689.

https://doi.org/10.1182/blood-2007-07-101576

Published: 2008

Includes: Supplemental data

Journal Articles

The JAK2-V617F Mutation Load Remains Stable over Several Years in Most Patients with Myeloproliferative Disorders Analyzed in a Retrospective Single Center Study.

Alexandre Theocharides, MD, Renate Looser, Hao-Shen Hui, Andreas S. Buser, MD, Alois Gratwohl, MD, Andre Tichelli, MD, Radek C. Skoda, MD

Blood (2007) 110 (11): 2526.

https://doi.org/10.1182/blood.V110.11.2526.2526

Published: 2007

Journal Articles

Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.

Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Heinz Gissingler, Robert Kralovics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola

Blood (2007) 110 (11): 263.

https://doi.org/10.1182/blood.V110.11.263.263

Published: 2007

Journal Articles

Leukemic blasts in transformed JAK2-V617F –positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Alexandre Theocharides, Marjorie Boissinot, François Girodon, Richard Garand, Soon-Siong Teo, Eric Lippert, Pascaline Talmant, Andre Tichelli, Sylvie Hermouet, Radek C. Skoda

Blood (2007) 110 (1): 375–379.

https://doi.org/10.1182/blood-2006-12-062125

Published: 2007

Includes: Supplemental data

Journal Articles

Myeloid Blasts in Transformed JAK2-V617F Positive Myeloproliferative Disorders Are Frequently Negative for the JAK2-V617F Mutation.

Alexandre Theocharides, Marjorie Boissinot, Richard Garand, François Girodon, Soon-Siong Teo, Eric Lippert, Andre Tichelli, Sylvie Hermouet, Radek C. Skoda

Blood (2006) 108 (11): 375.

https://doi.org/10.1182/blood.V108.11.375.375

Published: 2006

Journal Articles

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Robert Kralovics, Soon-Siong Teo, Sai Li, Alexandre Theocharides, Andreas S. Buser, Andre Tichelli, Radek C. Skoda

Blood (2006) 108 (4): 1377–1380.

https://doi.org/10.1182/blood-2005-11-009605

Published: 2006

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TP53 Deficiency in AML Confers Resistance to CAR T-Cells That Can be Overcome By Targeting the Cholesterol or Wnt Pathways

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Characterization of Hematopoietic Differentiation Profiles of MPN Patient-Derived Inducible Pluripotent Stem Cells Harboring Homozygous Vs Heterozygous Calreticulin Mutations

Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPα-Transgenic-Human-TPO-Expressing RAG2 -/- , IL2Rγ -/- Immunodeficient Mice

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2 -V617F mutations

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

The JAK2-V617F Mutation Load Remains Stable over Several Years in Most Patients with Myeloproliferative Disorders Analyzed in a Retrospective Single Center Study.

Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.

Leukemic blasts in transformed JAK2-V617F –positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Myeloid Blasts in Transformed JAK2-V617F Positive Myeloproliferative Disorders Are Frequently Negative for the JAK2-V617F Mutation.

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only